Closely monitor patients w/ existing or family history of porphyria during treatment. Assess couple's infertility & evaluate putative CI for pregnancy before starting treatment; evaluate for hypothyroidism, adrenocortical deficiency, hyperprolactinemia & appropriate specific treatment given. Ovarian hyperstimulation syndrome (OHSS); monitor stimulation cycles by ultrasound scans & oestradiol measurements; discontinue use if severe OHSS occurs. Increased incidence of multiple pregnancy & pregnancy loss by miscarriage or abortion in patients undergoing ovulation induction or ART. Carefully monitor ovarian response. Risk of ectopic pregnancy in women w/ history of tubal disease. Possible ovarian & other reproductive system neoplasms in women undergoing multiple treatment regimens for infertility. Congenital malformation. Risk of thromboembolic events. Contains Na <1 mmol. Renal & hepatic impairment. Not indicated during pregnancy & lactation. No relevant use in paed population & elderly.